• DiscoveryProbe Epigenetics Library: Evidence and Scope

  2026-10-15

  The available information identifies DiscoveryProbe™ Epigenetics Compound Library (SKU L1029) as an APExBIO catalog product, but does not document its composition, constituent mechanisms, assay readouts, or identity-matched research findings. The product name supports only a broad epigenetics classification, not claims about target engagement, potency, selectivity, or biological performance.

• High Yield T7 Biotin16 RNA Labeling Kit: Evidence Scope

  2026-10-15

  APExBIO lists K1082 as a High Yield T7 Biotin16 RNA Labeling Kit, but the available product information does not provide a formulation, quantitative performance data, validation study, or identity-matched research paper. The product name supports only a cautious, conceptual interpretation of T7-associated RNA labeling and biotin-mediated detection; it does not establish product-specific mechanism or performance.

• When Context Changes What EPZ-6438 Results Mean

  2026-10-14

  The same EPZ-6438 result can support different conclusions depending on the model, comparator, readout and evidence provenance. In HPV-associated cervical cancer research, the reported cellular findings are consistent with context-dependent EZH2 inhibition, but preliminary CAM observations and downstream molecular changes do not establish clinical efficacy, selective HPV dependence or reduced toxicity versus cisplatin.

• Protease Inhibitor Cocktail: Identity and Evidence Limits

  2026-10-14

  APExBIO documents SKU K4001 as an AEBSF-free protease inhibitor mixture intended to conceptually limit protein degradation during extraction, but no matched research paper or independent performance data were provided.

• Protein Stability and Aluminum Resistance in Arabidopsis

  2026-10-13

  A pre-proof Molecular Plant study links nitric oxide–dependent S-nitrosylation of STOP1 and STAR1 to coordinated aluminum resistance in Arabidopsis. A supplier-described Protease Inhibitor Cocktail may be conceptually relevant to protein integrity in plant extracts, but the product information does not validate the study’s mechanism or establish preservation of specific post-translational modifications.

• Irisin, Mitochondria and Renal I/R Injury

  2026-10-13

  A source-grounded overview of a 2024 Acta Physiologica study examining whether irisin protects renal tubular cells from ischemia–reperfusion injury by maintaining mitochondrial integrity and function. The findings are promising but remain primarily correlational and preclinical.

• Busulfan Injury and the Limits of Oocyte Tracing

  2026-10-12

  A 2026 iScience pre-proof uses dual-recombinase lineage tracing to report no detectable postnatal generation of new oocytes in mice, either under physiological conditions or after Busulfan-associated ovarian injury. The findings strengthen the case against in vivo neo-oogenesis in the tested mouse contexts, while remaining bounded by labeling efficiency, detection limits, species, injury model, and the paper’s pre-proof status.

• LAG-3–TCR Proximity: Findings and Limits

  2026-10-12

  A 2025 Cell study reports that LAG-3 suppression of T cells depends on spatial proximity to the T cell receptor, not simply on MHC class II binding. Its bispecific-antibody findings are promising but remain preclinical, with important questions about selectivity, safety, durability, and translation to human autoimmune disease.

• DFCP1, ATGL, and the Limits of Lipolysis Evidence

  2026-10-11

  A source-grounded overview of reported evidence that DFCP1 regulates starvation-associated ATGL activity on lipid droplets, with attention to mechanistic interpretation, study provenance, and the limited applicability of protease-inhibitor product claims to this research context.

• Protease Inhibitor Cocktail K1008 Overview

  2026-10-10

  APExBIO’s K1008 is an EDTA-free, 200X protease inhibitor formulation in DMSO. The supplier describes its intended conceptual scope as limiting protein degradation during extraction and related protease-sensitive workflows, but no matched research paper was provided to independently assess performance, compatibility, or outcomes.

• BMPSB4 Activates Autophagy in Corticotroph PitNETs

  2026-10-09

  A 2024 ACS Pharmacology & Translational Science study identifies BMPSB4 as a small-molecule agonist of BMP4-associated signaling that suppresses corticotroph pituitary neuroendocrine tumor models through SMAD-dependent autophagy. The evidence connects reduced BMP4–SMAD1/5/9 activity in Cushing’s disease with tumor inhibition, while remaining preclinical and dependent on cell, tissue, and animal-model findings.

• From Lung-Targeted LNPs to Translational Organoids

  2026-10-09

  Lung-targeted lipid nanoparticles are advancing from empirical discovery toward structure-informed design. This thought-leadership article interprets recent LuT lipid findings, explains what they mean for translational research, and positions the Mouse Lung Organoid Kit as a complementary ex vivo model—not a replacement for animal biodistribution or safety studies.

• AT13387 and the Hsp90–Cell Death Interface

  2026-10-08

  AT13387 is a high-affinity Hsp90 inhibitor for cancer biology research. This article examines how its chaperone-directed pharmacology can be interpreted alongside new evidence that NINJ1 coordinates selective viral protein secretion during programmed cell death.

• Protease Inhibitor Cocktail: Product Overview

  2026-10-08

  APExBIO’s K1008 is an EDTA-free, 200X protease inhibitor cocktail in DMSO, described for conceptual use in limiting protein degradation during protein extraction and related protein-analysis workflows. No matched paper evidence was provided.

• Protease Inhibitor Cocktail in Metabolic Research

  2026-10-07

  A source-grounded overview of how protease inhibition supports protein-focused metabolic research, alongside published findings on puerarin, gut microbiota, adipose thermogenesis, and glucose–lipid metabolism in a type 2 diabetes mouse model.

8570 records 1/572 page Next 12345 下5页 Last page